BioSpace News Archive

GE HealthCare has received U.S. FDA 510 Clearance for the new version of Digital Expert Access with remote scanning, the first remote patient scan solution with 510 Clearance.

Cell-Easy, a French Contract Development and Manufacturing Organization (CDMO) focused on advanced cell therapies, and the Toulouse University Hospital

Pharming Group N.V. announces that the first patient has been dosed in its Phase III pediatric clinical trial evaluating a new pediatric formulation of the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta inhibitor, in children ages one to six years, with activated phosphoinositide 3-kinase delta syndrome.

Sandoz, the global leader in generic and biosimilar medicines, announces the launch of Hyrimoz® citrate-free high concentration formulation in Europe.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will present at the SEB Annual Healthcare Seminar on Thursday, November 23, 2023, in Stockholm, Sweden.

BD, a leading global medical technology company, announced that Ronald Silverman, MD, FACS, has been named executive vice president and chief medical officer of BD, effective Dec. 4, 2023.

Apellis Pharmaceuticals, Inc., announced that the company will host a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 10:00 a.m. ET.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023.

Milestone Pharmaceuticals Inc. announced that members of its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023, at 10:30 a.m. Eastern Time.

Senhwa Biosciences, Inc. announced that U.S. Food and Drug Administration has approved its Phase II IND application of Silmitasertib to treat patients with community-acquired pneumonia caused by viral infection.